Role of Mesenchymal Stem Cell Therapy in Cisplatin Induced Nephrotoxicity in Adult Albino Rats: Ultrastructural & Biochemical Study.
Loading...
Date
2014-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: Mesenchymal stem cells (MSCs) have generated a great deal of excitement and promise as a potential source of cells for
cell-based therapeutic strategies. These data provide the clue of using MSCs in the current work in correcting cisplatin-induced
nephrotoxicity, the severest adverse effect of the well-known anticancer drug; cisplatin. Methods: MSCs of bone marrow origin
of femora and tibiae of adult albino rats were separated, grown, propagated in culture then identified by both morphology and
CD29 surface marker detection. MSCs were injected into the rats’’ tail veins one day after a single dose (5 mg/kg body weight) of
intraperitoneal injection of cisplatin. Four weeks later kidney tissue was examined histopathologically and ultra-structurally. Renal
functions s(urea, creatinine) as well as serum electrolytes levels (Na, K) were estimated Results: Cisplatin group demonstrated
atrophied glomeruli, thickened glomerular basement membrane, dilated urinary space, loss of proximal convoluted tubules brush
borders, loss of podocyte pedicels and collagen deposition. Tubular cells showed vacuolization and nuclear membrane degeneration.
Serum levels of urea, creatinine, Na and K were significantly elevated. MSCs ameliorated cisplatin-induced nephrotoxicity to a great
extent as evidenced histologically, ultra-structurally and biochemically. Conclusion: MSCs have a potential therapeutic effect against
cisplatin induced nephrotoxicity.
Description
Keywords
Mesenchymal stem cells, Cisplatin, Kidney, Ultra-structures
Citation
Ghaly Emad Nagiwub, Gergis Safwat Wadie, Aziz Joseph Naeim, Yassa Hanan Dawood, Hassan Hassan Abdel-Raheem. Role of Mesenchymal Stem Cell Therapy in Cisplatin Induced Nephrotoxicity in Adult Albino Rats: Ultrastructural & Biochemical Study. Acta Medica International. 2014 Jul-Dec; 1(2): 57-66.